ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLG2128

A development code.

Its studies are mostly in Osteoporosis, led by Qilu Pharmaceutical.

Furthest: phase 3, since Mar 20, 20251 company-led study, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 3since Mar 20, 2025Mar 20, 2025May 2027phase 3 · NCT06898060

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2025First study: phase 3 study in Postmenopausal Women With OsteoporosisFirst studyNCT06898060 · 282 planned

Ahead

  1. May 2027Primary completion: phase 3 study in Postmenopausal Women With OsteoporosisNCT06898060

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06898060Postmenopausal Women With Osteoporosis3Not yet recruitingMay 2027282

How it is read

Names in the registry

  • “QLG2128”, 1 entry

Codes read as this program: QLG2128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.